Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ENZN NASDAQ:IDRA NASDAQ:MBOT NASDAQ:PTE NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENZNEnzon Pharmaceuticals$0.08+6.4%$0.08$0.06▼$0.24$5.89M0.3516,733 shs16,318 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsMBOTMicrobot Medical$3.19+3.2%$3.20$0.85▼$4.67$168.42M1.227.06 million shs7.37 million shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsWINTWindtree Therapeutics$0.08+6.8%$0.44$0.06▼$173.00$2.38M0.575.36 million shs131,417 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENZNEnzon Pharmaceuticals+6.44%-2.10%-4.23%-2.10%-40.06%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MBOTMicrobot Medical+3.24%-21.23%-3.63%+32.37%+244.72%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics+6.84%+32.68%-26.18%-85.75%-99.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENZNEnzon Pharmaceuticals$0.08+6.4%$0.08$0.06▼$0.24$5.89M0.3516,733 shs16,318 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsMBOTMicrobot Medical$3.19+3.2%$3.20$0.85▼$4.67$168.42M1.227.06 million shs7.37 million shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsWINTWindtree Therapeutics$0.08+6.8%$0.44$0.06▼$173.00$2.38M0.575.36 million shs131,417 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENZNEnzon Pharmaceuticals+6.44%-2.10%-4.23%-2.10%-40.06%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MBOTMicrobot Medical+3.24%-21.23%-3.63%+32.37%+244.72%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics+6.84%+32.68%-26.18%-85.75%-99.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENZNEnzon Pharmaceuticals 0.00N/AN/AN/AIDRAIdera Pharmaceuticals 0.00N/AN/AN/AMBOTMicrobot Medical 2.50Moderate Buy$12.00276.18% UpsidePTEPolarityTE 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.00430,934.48% UpsideCurrent Analyst Ratings BreakdownLatest PTE, WINT, ENZN, MBOT, and IDRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $12.008/21/2025MBOTMicrobot MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENZNEnzon Pharmaceuticals$30K196.16$0.01 per share7.56$0.04 per share1.98IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AMBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/APTEPolarityTE$810K0.00N/AN/A$2.30 per share0.00WINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENZNEnzon Pharmaceuticals$780K-$0.03N/A∞N/AN/A-91.38%-4.03%11/3/2025 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AMBOTMicrobot Medical-$11.44M-$0.58N/AN/AN/AN/A-76.27%-67.54%11/12/2025 (Estimated)PTEPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/AWINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-207.34%-50.19%11/25/2025 (Estimated)Latest PTE, WINT, ENZN, MBOT, and IDRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025WINTWindtree Therapeutics-$99.00-$3.06+$95.94-$3.06$3.00 millionN/A8/14/2025Q2 2025ENZNEnzon PharmaceuticalsN/A-$0.02N/A-$0.02N/AN/A8/12/2025Q2 2025MBOTMicrobot Medical-$0.08-$0.10-$0.02-$0.10$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENZNEnzon PharmaceuticalsN/A55.7155.71IDRAIdera PharmaceuticalsN/A1.561.56MBOTMicrobot MedicalN/A12.0612.06PTEPolarityTEN/A4.114.11WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENZNEnzon PharmaceuticalsN/AIDRAIdera Pharmaceuticals12.18%MBOTMicrobot Medical16.30%PTEPolarityTE11.75%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipENZNEnzon Pharmaceuticals0.40%IDRAIdera Pharmaceuticals5.05%MBOTMicrobot Medical4.74%PTEPolarityTE5.40%WINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENZNEnzon PharmaceuticalsN/A74.21 million73.92 millionNot OptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableMBOTMicrobot Medical2052.79 million50.29 millionOptionablePTEPolarityTE427.38 million6.98 millionOptionableWINTWindtree Therapeutics3029.33 million3.66 millionNot OptionablePTE, WINT, ENZN, MBOT, and IDRA HeadlinesRecent News About These CompaniesShort Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 70.8%September 13, 2025 | americanbankingnews.comWindtree Therapeutics Approves Key Financial Structure ChangesSeptember 3, 2025 | msn.comWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingSeptember 2, 2025 | markets.businessinsider.comWindtree Therapeutics, Inc. Stockholders Approve Strategic Shift Toward Environmental Services and Biotech PartnershipsSeptember 2, 2025 | quiverquant.comQWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comBNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting NoticeAugust 22, 2025 | thecurrencyanalytics.comTBNB treasury company plunges 77% after Nasdaq delisting noticeAugust 22, 2025 | cointelegraph.comBNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delistingAugust 20, 2025 | fxstreet.comNasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%August 20, 2025 | coingape.comCWindtree Therapeutics Faces Nasdaq Delisting NoticeAugust 20, 2025 | msn.comWindtree Therapeutics Delays Q2 2025 Report FilingAugust 14, 2025 | tipranks.comWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025August 11, 2025 | globenewswire.comWindtree Therapeutics Terminates SEISMiC-C Clinical StudyAugust 11, 2025 | theglobeandmail.comWindtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study ResultsAugust 7, 2025 | msn.comWindtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock PatientsAugust 5, 2025 | taiwannews.com.twTWindtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy RolloutJuly 30, 2025 | msn.comWindtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and RedemptionJuly 29, 2025 | globenewswire.comWindtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto PivotJuly 26, 2025 | thecurrencyanalytics.comTWindtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time HighJuly 26, 2025 | techstory.inTWindtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency HoldingsJuly 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025Top 5 September Stock Picks: Market Tailwinds Drive New MomentumBy Thomas Hughes | September 1, 2025What to Expect From the Q3 Reporting SeasonBy Thomas Hughes | September 3, 20253 Gold ETFs That Could Surge If the Fed Cuts Rates This MonthBy Jordan Chussler | September 1, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025PTE, WINT, ENZN, MBOT, and IDRA Company DescriptionsEnzon Pharmaceuticals OTCMKTS:ENZN$0.08 +0.00 (+6.44%) As of 09/19/2025 03:44 PM EasternEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Idera Pharmaceuticals NASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Microbot Medical NASDAQ:MBOT$3.19 +0.10 (+3.24%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.25 +0.06 (+1.88%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.PolarityTE NASDAQ:PTEPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.Windtree Therapeutics NASDAQ:WINT$0.08 +0.01 (+6.84%) As of 09/19/2025 03:53 PM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
